PubRank

Julio C Medina

Author PubWeight™ 26.72‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Gene expression analysis of host innate immune responses during Lethal H5N1 infection in ferrets. J Virol 2008 2.23
2 Structure-based design of novel inhibitors of the MDM2-p53 interaction. J Med Chem 2012 2.01
3 Antagonism of CXCR3 inhibits lung metastasis in a murine model of metastatic breast cancer. Cancer Res 2006 1.58
4 Imidazo-pyrazine derivatives as potent CXCR3 antagonists. Bioorg Med Chem Lett 2009 1.40
5 AMG 837: a potent, orally bioavailable GPR40 agonist. Bioorg Med Chem Lett 2011 1.13
6 Discovery of AMG 232, a potent, selective, and orally bioavailable MDM2-p53 inhibitor in clinical development. J Med Chem 2014 1.08
7 Antagonism of chemokine receptor CXCR3 inhibits osteosarcoma metastasis to lungs. Int J Cancer 2009 1.04
8 Discovery and optimization of a novel series of GPR142 agonists for the treatment of type 2 diabetes mellitus. Bioorg Med Chem Lett 2012 1.03
9 Phenylalanine derivatives as GPR142 agonists for the treatment of type II diabetes. Bioorg Med Chem Lett 2012 1.01
10 Discovery and in vivo evaluation of (S)-N-(1-(7-fluoro-2-(pyridin-2-yl)quinolin-3-yl)ethyl)-9H-purin-6-amine (AMG319) and related PI3Kδ inhibitors for inflammation and autoimmune disease. J Med Chem 2014 0.93
11 CXCR3 antagonism impairs the development of donor-reactive, IFN-gamma-producing effectors and prolongs allograft survival. Transplantation 2009 0.91
12 Rational design and binding mode duality of MDM2-p53 inhibitors. J Med Chem 2013 0.89
13 Selective and potent morpholinone inhibitors of the MDM2-p53 protein-protein interaction. J Med Chem 2014 0.88
14 Optimization of 2-aminothiazole derivatives as CCR4 antagonists. Bioorg Med Chem Lett 2006 0.82
15 Identification of piperazine-bisamide GHSR antagonists for the treatment of obesity. Bioorg Med Chem Lett 2010 0.82
16 An expeditious synthesis of the MDM2-p53 inhibitor AM-8553. J Am Chem Soc 2012 0.81
17 An inhibitory metabolite leads to dose- and time-dependent pharmacokinetics of (R)-N-{1-[3-(4-ethoxy-phenyl)-4-oxo-3,4-dihydro-pyrido[2,3-d]pyrimidin-2-yl]-ethyl}-N-pyridin-3-yl-methyl-2-(4-trifluoromethoxy-phenyl)-acetamide (AMG 487) in human subjects after multiple dosing. Drug Metab Dispos 2008 0.81
18 Discovery of potent and specific CXCR3 antagonists. Bioorg Med Chem Lett 2011 0.81
19 Novel inhibitors of the MDM2-p53 interaction featuring hydrogen bond acceptors as carboxylic acid isosteres. J Med Chem 2014 0.80
20 Discovery of AMG 925, a FLT3 and CDK4 dual kinase inhibitor with preferential affinity for the activated state of FLT3. J Med Chem 2014 0.79
21 Optimization of the heterocyclic core of the quinazolinone-derived CXCR3 antagonists. Bioorg Med Chem Lett 2007 0.78
22 Discovery and optimization of a novel series of liver X receptor-alpha agonists. Bioorg Med Chem Lett 2005 0.78
23 Discovery and in vivo evaluation of dual PI3Kβ/δ inhibitors. J Med Chem 2012 0.77
24 Discovery, Optimization, and in Vivo Evaluation of Benzimidazole Derivatives AM-8508 and AM-9635 as Potent and Selective PI3Kδ Inhibitors. J Med Chem 2015 0.77
25 Optimization of triazoles as novel and potent nonphlorizin SGLT2 inhibitors. Bioorg Med Chem Lett 2011 0.77
26 Discovery and optimization of arylsulfonyl 3-(pyridin-2-yloxy)anilines as novel GPR119 agonists. Bioorg Med Chem Lett 2013 0.77
27 Optimization of phenylacetic acid derivatives for balanced CRTH2 and DP dual antagonists. Bioorg Med Chem Lett 2011 0.76
28 Discovery of AM-7209, a potent and selective 4-amidobenzoic acid inhibitor of the MDM2-p53 interaction. J Med Chem 2014 0.76
29 Design and optimization of imidazole derivatives as potent CXCR3 antagonists. Bioorg Med Chem Lett 2007 0.76
30 Optimization of phenylacetic acid derivatives for CRTH2 and DP selective antagonism. Bioorg Med Chem Lett 2011 0.75